Izvorni kod stranice Trastuzumab

{{Drugbox-lat
| IUPAC_name        = 
| image             = HerceptinFab.jpg
| width             = 
| alt               = 
| image2            = 
| width2            = 
| alt2              = 
| imagename         = 
| drug_name         = Trastuzumab
| caption           =

<!-- Clinical data -->
| tradename         = 
| Drugs.com         = {{drugs.com-lat|monograph|Trastuzumab}}
| MedlinePlus       = 
| licence_EU        = 
| licence_US        = 
| DailyMedID        = 
| pregnancy_AU      = 
| pregnancy_US      = 
| pregnancy_category= 
| legal_AU          = 
| legal_CA          = 
| legal_UK          = 
| legal_US          = 
| legal_status      = 
| dependency_liability = 
| routes_of_administration = Intravenozno

<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 28,5 dana
| excretion         =

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|}}
| CAS_number        = 180288-69-1
| CAS_supplemental  = 
| ATCvet            = 
| ATC_prefix        = L01
| ATC_suffix        = XC03
| ATC_supplemental  = 
| PubChem           = 
| PubChemSubstance  = 
| IUPHAR_ligand     = 
| DrugBank_Ref      = {{drugbankcite|correct|drugbank}}
| DrugBank          = DB00072
| ChemSpiderID_Ref  = {{chemspidercite|correct|chemspider}}
| ChemSpiderID      = 
| UNII_Ref          = {{fdacite|correct|FDA}}
| UNII              = 
| KEGG_Ref          = {{keggcite|correct|kegg}}
| KEGG              = 
| ChEBI_Ref         = {{ebicite|correct|EBI}}
| ChEBI             = 
| ChEMBL_Ref        = {{ebicite|correct|EBI}}
| ChEMBL            = 1201585
| synonyms          =

<!-- Chemical data -->
 | C=6470 | H=10012 | N=1726 | O=2013 | S=42
 | molecular_weight = 145531,5 g/mol
| smiles            = 
| StdInChI          = 
| StdInChIKey_Ref   = {{stdinchicite|correct|chemspider}}
| StdInChI_comment  = 
| StdInChIKey       = 
| StdStdInChI_Ref   = {{stdinchicite|correct|chemspider}}
| density           = 
| melting_point     = 61
| melting_high      = 
| melting_notes     = 
| boiling_point     = 
| boiling_notes     = 
| solubility        = 
| specific_rotation = 
| sec_combustion    = 
}}
'''Trastuzumab''' ([[International Nonproprietary Name|INN]]; ''Herclon'', ''Herceptin'') je [[monoklonalno antitelo]] koje je specifično za [[HER2/neu]] [[Receptor (biohemija)|receptor]]. Njegova glavna primena je u lečenju pojedinih tipova [[rak dojke|raka dojke]]. Trastuzumab je rekombinantno IgG1 kapa, humanizovano monoklonalno antitelo koje se selektivno vezuje sa visokim afinitetom za ekstracelularni domen ljudskog receptora epidermalnog faktora rasta. Ovo antitelo se proizvodi u CHO ćelijskoj kulturi.<ref>Bange J, Zwick E, Ullrich A: Molecular targets for breast cancer therapy and prevention. Nat Med. 2001 May;7(5):548-52. [[PubMed|PMID]] [http://www.ncbi.nlm.nih.gov/pubmed/11329054 11329054]</ref><ref>Menard S, Pupa SM, Campiglio M, Tagliabue E: Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003 Sep 29;22(42):6570-8. [[PubMed|PMID]] [http://www.ncbi.nlm.nih.gov/pubmed/14528282 14528282]</ref><ref>Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, Mitchell T, Vaughn JP: Development of Herceptin resistance in breast cancer cells. Cytometry A. 2004 Feb;57(2):86-93. [[PubMed|PMID]] [http://www.ncbi.nlm.nih.gov/pubmed/14750129 14750129]</ref><ref>Albanell J, Codony J, Rovira A, Mellado B, Gascon P: Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol. 2003;532:253-68. [[PubMed|PMID]] [http://www.ncbi.nlm.nih.gov/pubmed/12908564 12908564]</ref><ref>Tan AR, Swain SM: Ongoing adjuvant trials with trastuzumab in breast cancer. Semin Oncol. 2003 Oct;30(5 Suppl 16):54-64. [[PubMed|PMID]] [http://www.ncbi.nlm.nih.gov/pubmed/14613027 14613027]</ref><ref>IGMT Link:http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=7637 {{Webarchive|url=https://web.archive.org/web/20081207032306/http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=7637 |date=2008-12-07 }}</ref><ref>IGMT Link:http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=1N8Z {{Webarchive|url=https://web.archive.org/web/20081207054010/http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=1N8Z |date=2008-12-07 }}</ref><ref>{{Cite pmid|21059682|noedit}}</ref><ref>{{cite pmid|18048412|noedit}}</ref>

== Reference ==
{{reflist|2}}

== Literatura ==
{{refbegin}}
* {{GoodmanGilman10th}}
* {{FoyePrinciplesMedChem6th}}
{{refend}}
== Spoljašnje veze ==
{{Portal-lat|Medicina|Hemija}}
{{Commonscat-lat|Trastuzumab}}
* [http://www.drugbank.ca/drugs/DB00072 Trastuzumab]

{{HumanizovaniMonoklonali}}

[[Kategorija:Hemoterapijski agensi]]
[[Kategorija:Monoklonalna antitela za tumore]]